Richard Van der Jagt, M.D.

Chair, Canadian Leukemia Studies Group at Ottawa Hospital and Hospital & Health Care Consultant

Dr. Richard Van der Jagt is an active clinician/researcher who continues to chair the Canadian Leukemia Studies Group which he founded. This national group has now expanded to include centers across Canada, USA and with interested collaborators in Sweden, Israel, China and Argentina. This group has completed a large randomized CIHR/Industry funded study in AML which demonstrates a statistically significant advantage of a novel regimen over standard chemotherapy. Dr. Van der Jagt has developed a new clinical trial based on that data and has submitted that trial to the National Cancer Institute (US) peer review. 23 centers in Canada, U.S. A. and Israel have agreed to participate in the new trial. This group is also actively involved in studies in myelodysplasia, lymphoma and myeloma. Dr. Van der Jagt is active in undergraduate and postgraduate teaching, and continues to be an active member of the Ottawa Hospital Research Ethics Board.

Click this link for WM clinical trials under Dr. Van der Jagt.

Contact Info:
501 Smyth Road
Ottawa, ON, Canada K1H 8L6
Tel: 613-737-8899 ext. 78804
Fax: 613-739-6227